Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Wyeth
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A Phase 3, Open-label Study to Evaluate Persistence of the Antibody Response Elicited by Pneumococcal Conjugate Vaccine in Healthy Children Who Have Been Previously Immunized With a 4-Dose Series of a Pneumococcal Conjugate Vaccine During Infancy in Study 6096A1-008-EU and the Safety and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Administered at Least 24 Months After the Last Toddler Dose of Pneumococcal Conjugate Vaccine
To evaluate the antibody levels to the 13 pneumococcal vaccine serotypes not earlier than 24 months after the administration of the toddler dose in study 6096A1-008-EU, as measured by serotype-specifi...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 4 ans
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, LONG-TERM EXTENSION STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY LONG TERM EFFICACY OF LECOZOTAN (SRA-333) SR IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE
Primary: To evaluate the safety and tolerability of long-term therapy with three dose levels (2, 5, 10 mg daily) of Lecozotan (SRA-333) SR administered to patients with mild to moderate Alzheimer’s ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Wyeth
Update Il y a 4 ans
WYETH 3129K5-2005 : Essai de phase 2 évaluant l’efficacité d’un traitement associant de l’inotuzumab ozogamicin à du rituximab chez des patients ayant un lymphome diffus à grandes cellules B CD20/22+, réfractaire ou en rechute et éligible à une greffe autologue de cellules souches. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
An open-label, single-arm, phase 2 study of inotuzumab ozogamicin plus rituximab in subjects with relapsed/refractory CD22-positive diffuse large b-cell lymphoma, eligible for autologous stem cell tra...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Wyeth
Update Il y a 4 ans
INTORACT : essai de phase 3 randomisé comparant l’efficacité de l'association du bévacizumab à du temsirolimus ou à de l’interféron alpha, en traitements de première ligne, chez des patients ayant un cancer du rein. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Phase 3b, randomized, open-label study of bevacizumab + temsirolimus vs. bevacizumab + interferon-alfa as first-line treatment in subjects with advanced renal cell carcinoma.
Country
France
organs
Rein
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Wyeth
Update Il y a 4 ans
WYETH 3144A1-2204 : Essai de phase 1-2 randomisé évaluant la tolérance d’un traitement associant du HKI-272 et de la vinorelbine, chez des patients ayant une tumeur solide ou un cancer du sein métastatique HER2+. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase 1/2 study of HKI-272 in combination with vinorelbine in subjects with solid tumors and metastatic breast cancer.
Country
France
organs
Sein
,
Tumeurs solides
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Wyeth
Update Il y a 4 ans
Wyeth 3129K3-101 : Essai de phase 1-2 évaluant la tolérance de l’association inotuzumab ozogamicin et rituximab chez des patients ayant un lymphome non hodgkinien. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de l’essai est de déterminer la dose d'inotuzumab ozogamicin maximale tolérée en association avec le rituximab, puis d’évaluer la tolérance et l’efficacité de cette association chez des pat...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals France
Update Il y a 4 ans
A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients with Active, Severe and Advanced Axial Ankylosing Spondylitis
To compare the efficacy of etanercept (50 mg, once weekly) with that of placebo in patients with active, severe and advanced Ankylosis Spondylitis (as defined by the modified New York criteria) at wee...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 4 ans
A MULTICENTER, OPEN LABEL SAFETY STUDY OF 2 DOSES OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INFANTS AGED LESS THAN 12 MONTHS WITH PRESUMED GERD
A MULTICENTER, OPEN LABEL SAFETY STUDY OF 2 DOSES OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INFANTS AGED LESS THAN 12 MONTHS WITH PRESUMED GERD
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals, Global Medical Affairs Department
Update Il y a 4 ans
A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects with Psoriasis Estudio aleatorizado y abierto para evaluar la seguridad y la eficacia del etanercept en el tratamiento de sujetos con psoriasis
To compare the efficacy of continuous versus intermittent ETN treatment regimens in subjects with psoriasis over 54 weeks
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals France
Update Il y a 4 ans
A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Auto-Injector and the Etanercept Prefilled Syringe) in Patients with Rheumatoid Arthritis
To compare patient satisfaction with two different delivery devices for etanercept after 12 weeks of use, using a 10 point scale form totally dissatisfied to totally satisfied.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next